ReviewImmunotherapy advances2022

Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer.

Tosca Holtrop et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.